$48.35
0.15% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Sanofi Sponsored ADR Stock price

$48.35
-5.99 11.02% 1M
-0.19 0.39% 6M
-1.38 2.78% YTD
+0.70 1.47% 1Y
-0.78 1.59% 3Y
+1.45 3.09% 5Y
+0.70 1.47% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.07 0.15%
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Key metrics

Market capitalization $121.22b
Enterprise Value $139.72b
P/E (TTM) P/E ratio 26.52
EV/FCF (TTM) EV/FCF 23.72
EV/Sales (TTM) EV/Sales 2.93
P/S ratio (TTM) P/S ratio 2.54
P/B ratio (TTM) P/B ratio 1.55
Dividend yield 4.21%
Last dividend (FY24) $2.04
Revenue growth (TTM) Revenue growth 5.18%
Revenue (TTM) Revenue $47.68b
EBIT (operating result TTM) EBIT $10.14b
Free Cash Flow (TTM) Free Cash Flow $5.89b
EPS (TTM) EPS $1.82
P/E forward 16.28
P/S forward 2.42
EV/Sales forward 2.79
Short interest 0.36%
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Sanofi Sponsored ADR forecast:

18x Buy
82%
2x Hold
9%
2x Sell
9%

Analyst Opinions

22 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
47,675 47,675
5% 5%
100%
- Direct Costs 18,371 18,371
9% 9%
39%
29,304 29,304
3% 3%
61%
- Selling and Administrative Expenses 6,830 6,830
10% 10%
14%
- Research and Development Expense 7,523 7,523
7% 7%
16%
14,951 14,951
8% 8%
31%
- Depreciation and Amortization 4,815 4,815
32% 32%
10%
EBIT (Operating Income) EBIT 10,136 10,136
1% 1%
21%
Net Profit 4,558 4,558
49% 49%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Negative
Reuters
4 days ago
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
Neutral
GlobeNewsWire
11 days ago
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would...
Neutral
GlobeNewsWire
12 days ago
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination wi...
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 87,994
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today